Physician profile
Timothy E Kval
NPI 1144399510
$1,758.80
in general payments reported to CMS, 2019-2025
29 companies · $27.83 in 2025
The $27.83 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,211 · 2020: $181 · 2021: $49.05 · 2022: $84.82 · 2023: $146 · 2024: $59.83 · 2025: $27.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $233.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $333.16 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $203.93 | 2019 | |
| Abbvie INC. | $117.26 | 2019-2025 | |
| Novo Nordisk INC | $112.66 | 2019-2022 | |
| Boston Scientific Corporation | $98.10 | 2023 | Watchman Access System |
| Amgen INC. | $84.71 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $81.85 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $78.61 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $76.84 | 2019 | |
| Medtronic Minimed, INC. | $74.67 | 2019 | |
| Grifols USA, LLC | $68.25 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.55 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $55.17 | 2019-2023 | Austedo |
| Ironshore Pharmaceuticals INC. | $41.50 | 2019 | |
| Tempus Ai, INC | $40.58 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $26.36 | 2019 | |
| Vanda Pharmaceuticals INC. | $19.75 | 2019 | |
| Insulet Corporation | $19.49 | 2020 | |
| Hologic Sales and Service, LLC | $17.61 | 2021 | |
| Alkermes, INC. | $17.54 | 2019 | |
| Smith+Nephew, INC. | $17.47 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.19 | 2019 | |
| Astellas Pharma US INC | $15.96 | 2020 | |
| Baxter Healthcare | $14.43 | 2023 | Hillrom - Welch Allyn Panoptic Ophthalmoscope |
| Mylan Specialty L.P. | $14.07 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.04 | 2023 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.05 | 2019 | |
| Shire North American Group INC | $12.10 | 2019 | |
| Glaxosmithkline, LLC. | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Kval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.